Please check your internet connection and try again.
# Lorazepam (Benzodiazepine)
## Overview
Lorazepam is a short-acting benzodiazepine with anxiolytic, sedative, hypnotic, and anticonvulsant properties. It acts by enhancing the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABAA receptor.
## Primary Indications
* Anxiety disorders
* Insomnia
* Status epilepticus (as first or second-line agent)
* Preoperative sedation
* Management of agitation
## Adult Dosing
* **Anxiety:** 0.5 mg to 2 mg orally 2 to 3 times daily. Maximum daily dose is generally 10 mg.
* **Insomnia:** 1 mg to 2 mg orally at bedtime.
* **Status Epilepticus:** 2 mg to 4 mg IV, may repeat after 5 to 10 minutes if seizures persist, not to exceed 8 mg in a 12-hour period.
* **Preoperative Sedation:** 1 mg to 4 mg IM or IV given 2 hours before surgery.
* **Agitation:** 0.5 mg to 2 mg IV or IM every 4 to 6 hours as needed.
Dosing for specific indications, especially in critical care settings, may vary based on institutional protocols and patient response.
## Pediatric Dosing
* **Status Epilepticus:** 0.1 mg/kg IV, not to exceed 4 mg per dose. May repeat once after 5 to 10 minutes. (Source: Pediatric Advanced Life Support guidelines).
* **Anxiety/Sedation:** Use in pediatric patients is generally limited due to potential for paradoxical reactions and lack of extensive data. Dosing is highly individualized and often initiated at very low doses (e.g., 0.01-0.03 mg/kg/dose PO/IM/IV) and titrated carefully. Consult specialized pediatric resources for guidance.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. Dose reduction may be necessary.
* **Renal Impairment:** Dose adjustments are generally not required for mild to moderate impairment, but caution is advised.
## Contraindications
* Known hypersensitivity to lorazepam, other benzodiazepines, or any component of the formulation.
* Acute narrow-angle glaucoma.
* Severe respiratory insufficiency.
* Severe hepatic insufficiency.
* Obstructive sleep apnea.
## Adverse Effects
* **Common:** Sedation, drowsiness, dizziness, weakness, ataxia.
* **Less Common:** Confusion, depression, memory impairment, paradoxical excitement, respiratory depression (especially with IV administration or in combination with other CNS depressants).
* **Serious:** Respiratory depression, anterograde amnesia, dependence, withdrawal symptoms, abuse potential, misuse.
## Key Drug Interactions
* **CNS Depressants (opioids, alcohol, other sedatives, antihistamines):** Additive CNS depression, leading to profound sedation, respiratory depression, coma, and death. Co-administration should be avoided or used with extreme caution and close monitoring.
* **CYP450 Inhibitors/Inducers:** Lorazepam is primarily metabolized by glucuronidation, not CYP450 enzymes, so significant interactions via this pathway are less common compared to other benzodiazepines. However, agents affecting glucuronidation could theoretically alter clearance.
## Monitoring
* Level of consciousness, respiratory rate, and oxygen saturation, particularly with IV administration or in patients with respiratory compromise.
* Signs of paradoxical excitement or agitation.
* Signs of withdrawal upon discontinuation.
* Potential for misuse or abuse.
## Clinical Pearls
* Lorazepam has a relatively short half-life compared to diazepam, making it useful for acute management and procedures where rapid onset and shorter duration of action are desired.
* IV lorazepam can be unpredictable in absorption and may cause pain on injection. IM injection is an alternative but absorption can be slower and more variable.
* Tolerance and dependence can develop with prolonged use. Discontinuation should be gradual to avoid withdrawal symptoms.
* The "black box" warning regarding the risks of using benzodiazepines with opioid analgesics should be reviewed.
---
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional guidelines for definitive patient care decisions.*
